Vaccine HAVRIX 1440 (Adult) – (4,600) at Dr. Essa Lab

Vaccine HAVRIX 1440 (Adult) – (4,600) at Dr. Essa Lab

The Vaccine HAVRIX 1440 (Adult) – (4,600) at Dr. Essa Lab is a premier preventive healthcare service designed to provide robust, long-term active immunity against the Hepatitis A virus (HAV). Hepatitis A is a highly contagious liver infection caused by the Hepatitis A virus, primarily transmitted through the fecal-oral route, contaminated food, or water. While childhood exposure often results in mild or asymptomatic infections, contracting Hepatitis A during adulthood can lead to severe clinical manifestations, including acute icteric hepatitis, prolonged cholestasis, and in rare cases, life-threatening fulminant hepatic failure. To mitigate these risks, Dr. Essa Laboratory & Diagnostic Centre offers the Havrix 1440 vaccine, an internationally recognized, sterile suspension containing inactivated Hepatitis A virus (HM175 strain) adsorbed onto aluminum hydroxide as an adjuvant.

This vaccine works by introducing inactivated viral antigens into the body, which stimulates the immune system to produce specific anti-HAV neutralizing antibodies (specifically IgG) without causing the disease itself. The “1440” designation represents the antigen content (1440 ELISA Units of viral protein per 1.0 mL dose), which is the standard highly immunogenic dose recommended for adults aged 19 years and older. Administered as an intramuscular injection, the Vaccine HAVRIX 1440 (Adult) – (4,600) at Dr. Essa Lab provides exceptional diagnostic and clinical value by establishing a protective antibody threshold that prevents acute hepatic inflammation and safeguards public health. Immunization not only protects the individual but also contributes to herd immunity, reducing the overall burden of viral hepatitis in the community.

Clinical Procedure: What to Expect

Patient Preparation

To ensure maximum safety and efficacy during the administration of the Vaccine HAVRIX 1440 (Adult) – (4,600) at Dr. Essa Lab, patients are advised to adhere to the following preparation guidelines:

• Medical History Disclosure: Inform the healthcare professional of any known allergies, particularly to neomycin (an antibiotic used in trace amounts during vaccine manufacturing) or any components of the vaccine, including aluminum hydroxide.
• Current Health Status: If you are experiencing a moderate-to-severe acute illness accompanied by a high fever, it is clinically appropriate to postpone the vaccination until you have fully recovered. Mild illnesses, such as a common cold, do not require postponement.
• Medication Review: Disclose all current medications, especially immunosuppressive therapies, chemotherapy, or systemic corticosteroids, as these may reduce the immunological response to the vaccine.
• Bleeding Disorders: Inform the nurse if you have a bleeding disorder, such as hemophilia, or are taking anticoagulant medications (e.g., warfarin) so that appropriate pressure can be applied to the injection site to prevent hematoma formation.
• No Fasting Required: There are no dietary restrictions or fasting requirements prior to receiving this vaccine. You may eat and drink normally.
• Comfortable Clothing: Wear loose-fitting clothing or a short-sleeved shirt to allow easy access to the deltoid muscle of the upper arm, which is the preferred anatomical site for administration.

During the Procedure

The administration of the Vaccine HAVRIX 1440 (Adult) – (4,600) at Dr. Essa Lab is conducted under strict aseptic conditions by highly trained clinical staff. The procedure involves the following steps:

• Patient Positioning: The patient is comfortably seated in a chair. The clinician will inspect the upper arm to locate the deltoid muscle.
• Site Preparation: The skin over the deltoid muscle is thoroughly cleansed with an isopropyl alcohol swab and allowed to air dry to prevent contamination.
• Vaccine Inspection: The clinician will visually inspect the pre-filled syringe of Havrix 1440 for any particulate matter or discoloration. The vaccine should appear as a homogeneous, turbid white suspension after shaking.
• Injection Technique: The vaccine is administered via intramuscular (IM) injection at a 90-degree angle into the deltoid muscle. Intramuscular administration is critical, as subcutaneous or intradermal injection may result in suboptimal antibody response.
• Duration: The actual injection process takes less than a minute.
• Post-Administration Care: A sterile cotton ball or adhesive bandage is applied to the injection site with gentle pressure. Patients are advised to remain in the waiting area for approximately 15 to 20 minutes post-injection to monitor for any immediate allergic reactions or vasovagal syncope (fainting).

When is a Vaccine HAVRIX 1440 (Adult) – (4,600) Performed?

International Travel to Endemic Areas

Physicians strongly recommend the Vaccine HAVRIX 1440 (Adult) – (4,600) at Dr. Essa Lab for individuals planning travel to geographic regions with high or intermediate endemicity of Hepatitis A. These regions often include parts of Asia, Africa, Central and South America, and Eastern Europe. Because travelers are frequently exposed to unfamiliar water sources and local food preparations, they face a heightened risk of contracting the virus. Administering the vaccine at least two to four weeks prior to departure ensures that the body has sufficient time to develop protective neutralizing antibodies, preventing debilitating travel-related hepatic illness.

Chronic Liver Disease Management

Patients diagnosed with pre-existing chronic liver conditions, including chronic Hepatitis B, Hepatitis C, non-alcoholic fatty liver disease (NAFLD), cirrhosis, or autoimmune hepatitis, are prime candidates for this vaccine. While Hepatitis A does not cause chronic infection, an acute HAV infection superimposed on an already compromised liver can trigger catastrophic liver failure. Immunizing these high-risk patients with Havrix 1440 is a vital preventive strategy to avoid acute-on-chronic liver failure, reducing morbidity and mortality in this vulnerable patient population.

Occupational Exposure Risks

Certain professions carry an elevated risk of exposure to the Hepatitis A virus, necessitating routine immunization. Healthcare workers, laboratory personnel handling viable HAV specimens, sewage and wastewater management workers, and daycare employees are frequently exposed to potentially infectious materials. Additionally, food handlers in the hospitality and food service industries are highly encouraged to get vaccinated, as they can inadvertently transmit the virus to large numbers of consumers if they become infected, sparking widespread public health outbreaks.

Lifestyle and Behavioral Risk Factors

Epidemiological data indicates that specific behavioral groups are at a significantly higher risk of acquiring Hepatitis A. This includes men who have sex with men (MSM), individuals who use illicit drugs (both injection and non-injection), and those experiencing homelessness or unstable housing conditions. In these cohorts, transmission is facilitated by close personal contact or compromised sanitary conditions. Providing the Vaccine HAVRIX 1440 (Adult) – (4,600) at Dr. Essa Lab offers a critical shield of protection, breaking the chain of transmission within these communities.

Outbreak Control and Post-Exposure Prophylaxis

The vaccine is also indicated for post-exposure prophylaxis (PEP) in unvaccinated individuals who have been recently exposed to the Hepatitis A virus (e.g., household contacts of an infected person or individuals exposed to a confirmed foodborne source). When administered within 14 days of exposure, the Havrix 1440 vaccine is highly effective in preventing active clinical disease or significantly reducing the severity of symptoms, serving as a rapid intervention tool for public health management.

What Does a Vaccine HAVRIX 1440 (Adult) – (4,600) Detect?

As an active immunizing agent, the Vaccine HAVRIX 1440 (Adult) – (4,600) at Dr. Essa Lab does not “detect” an active disease, but rather stimulates, establishes, and maintains specific immunological parameters to protect the body. Clinically, the administration of this vaccine is associated with the following physiological and protective outcomes:

• Stimulation of Anti-HAV IgG Antibodies: Induces the production of high-titer protective antibodies against the Hepatitis A virus.
• Prevention of Acute Icteric Hepatitis: Protects the hepatic parenchyma from viral-induced inflammation and subsequent jaundice.
• Prevention of Fulminant Hepatic Failure: Eliminates the risk of acute, life-threatening liver failure associated with severe HAV infection.
• Establishment of Long-Term Immunological Memory: Stimulates memory B-cells to provide rapid antibody production upon any future exposure to the wild virus.
• Reduction of Community Transmission: Lowers the viral load in the community, preventing fecal-oral transmission cycles.
• Protection Against Foodborne Outbreaks: Safeguards individuals from contracting the virus through contaminated commercial food products.
• Mitigation of Waterborne HAV Strains: Provides immunity against diverse waterborne genotypes of the Hepatitis A virus.
• Prevention of Cholestatic Hepatitis: Avoids the prolonged biliary obstruction and pruritus associated with atypical HAV presentations.
• Prevention of Relapsing Hepatitis A: Protects against the multiple waves of hepatic inflammation seen in relapsing forms of the disease.
• Avoidance of Elevated Transaminases (ALT/AST): Prevents the severe hepatocellular damage that causes liver enzymes to spike.
• Prevention of Hyperbilirubinemia: Keeps serum bilirubin levels normal by preventing viral destruction of hepatocytes.
• Prevention of Hepatomegaly and Splenomegaly: Avoids painful liver and spleen swelling associated with acute viral hepatitis.
• Protection for Immunocompromised Contacts: Indirectly protects vulnerable household members by preventing the vaccinee from becoming a vector.
• Post-Exposure Protection: Provides rapid active immunity when administered within the critical 14-day post-exposure window.
• Maintenance of Occupational Health Compliance: Ensures safety and regulatory compliance for high-risk clinical and industrial workers.
• Protection of Liver Transplant Recipients: Safeguards transplanted organs from graft-threatening acute viral infections.
• Prevention of Prolonged Prothrombin Time (PT/INR): Avoids coagulopathy associated with acute liver injury.
• Avoidance of Hospitalization: Reduces the clinical and financial burden of inpatient care for severe hepatitis symptoms.
• Prevention of Extrahepatic Manifestations: Protects against rare HAV-associated complications like cutaneous vasculitis and arthritis.
• Long-Term Cost Savings: Prevents expensive medical management of acute liver failure and potential liver transplantation.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Laboratory & Diagnostic Centre, patient convenience and accurate record-keeping are paramount. Upon receiving the Vaccine HAVRIX 1440 (Adult) – (4,600) at Dr. Essa Lab, patients are immediately provided with an official immunization card. This physical card contains critical details, including the vaccine brand name (Havrix 1440), batch number, expiration date, date of administration, and the scheduled date for the booster dose (typically 6 to 12 months after the initial dose to ensure lifetime immunity).

In addition to the physical card, Dr. Essa Lab utilizes an advanced digital reporting system. The vaccination record is uploaded to the laboratory’s secure online database within a few hours of administration. Patients can access their digital vaccination certificate and receipt through the official Dr. Essa Lab website or mobile application using their unique patient ID and password. This digital record serves as an invaluable document for international travel, employment verification, and personal health tracking, ensuring that your immunization history is always secure and accessible.

Vaccine HAVRIX 1440 (Adult) – (4,600) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-HAV IgG Antibody Level	Seropositive (>20 mIU/mL), indicating protective immunity.	Seronegative (<20 mIU/mL), indicating lack of immunity or non-response.
Injection Site Reaction	Mild localized transient erythema, slight swelling, or mild tenderness.	Severe localized pain, persistent induration, sterile abscess, or cellulitis (rare).
Systemic Immune Response	No systemic symptoms, or mild transient headache, fatigue, or low-grade fever.	High fever, severe myalgia, arthralgia, or acute anaphylactic reaction (extremely rare).
Liver Function Tests (ALT/AST)	Normal range (ALT: 7-56 U/L; AST: 10-40 U/L) post-exposure.	Markedly elevated transaminases (>1000 U/L) indicating acute HAV infection in unvaccinated individuals.
Serum Bilirubin Levels	Normal range (0.2-1.2 mg/dL) post-exposure.	Elevated bilirubin (jaundice) indicating acute hepatic dysfunction in unvaccinated individuals.
Clinical Symptoms of HAV	Asymptomatic, healthy state with no signs of viral hepatitis.	Nausea, vomiting, dark urine, pale stools, and abdominal pain in non-immunized patients.
Duration of Immunity	Long-term protection (estimated up to 20-25 years or lifetime after booster).	Waning immunity or incomplete protection if the second booster dose is omitted.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Vaccine HAVRIX 1440 (Adult) – (4,600)?

• Experienced Healthcare Professionals: Our clinical team consists of highly trained nurses and pathologists dedicated to safe vaccine administration.
• Patient-Focused Care: We prioritize patient comfort, offering detailed pre-vaccination counseling and post-administration monitoring.
• Quality Diagnostic Services: Dr. Essa Lab is a trusted name in Pakistan, known for maintaining the highest standards of clinical excellence.
• Cold Chain Integrity: We strictly maintain the vaccine cold chain (2°C to 8°C) from storage to administration, ensuring maximum vaccine potency.
• Convenient Locations: With numerous branches across Karachi and other cities, accessing your vaccine is simple and hassle-free.
• Digital Record Management: Access your immunization records and certificates anytime through our secure online portal.
• ISO Certified Standards: Our laboratories adhere to international quality management systems, ensuring reliable and safe healthcare delivery.
• Affordable and Transparent Pricing: We offer competitive pricing for premium preventive vaccines, ensuring community-wide accessibility.